IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, will release its Q3 2024 financial and operational results before Nasdaq market opening on November 26, 2024. The company will host a conference call and webcast at 10:00 AM EST the same day to discuss the results and corporate developments. The call will be accessible via US toll-free and international dial-in numbers, with a live webcast available through the company's website.

News Market Reaction – ICCM

-1.20%

-1.20% Session move

In the trading session that priced this news, ICCM declined 1.20%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day.

Conference call & webcast info:

Tuesday, November 26, 2024, at 10:00 am EST
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://Veidan.activetrail.biz/IcecureQ3-2024  
A recording of the webcast will be available at: ir.icecure-medical.com/ 

About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses its expected announcement of financial and operational results as of and for the nine months ended September 30, 2024 and hosting a conference call related to such results. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC") on April 3, 2024, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:

Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462

Logo - https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-third-quarter-2024-financial--operational-results-on-november-26-2024-302311232.html

SOURCE IceCure Medical

FAQ

When will IceCure Medical (ICCM) release Q3 2024 earnings?

IceCure Medical will release its Q3 2024 financial and operational results before the Nasdaq market opens on Tuesday, November 26, 2024.

How can I join IceCure Medical's (ICCM) Q3 2024 earnings call?

You can join the earnings call on November 26, 2024, at 10:00 AM EST via US toll-free number (1-888-407-2553), international number (+972-3-918-0696), or through the live webcast available at the company's website.

What is IceCure Medical's (ICCM) main technology focus?

IceCure Medical develops minimally-invasive cryoablation technology that destroys tumors by freezing them as an alternative to surgical tumor removal.